

**Persistent Asthma Study**

For more information call: 229-883-8909

**HZA106837A—GlaxoSmithKline (currently enrolling)**

A long-term, randomized, double-blind, parallel group study of Fluticasone Furoate/GW642444 inhalation powder once-daily and Fluticasone Furoate inhalation powder once-daily in subjects with asthma.

**Criteria for Enrollment:**

> 12 yrs age

h/o asthma x 1 yr..

daily minimum  
dose of 200 mcg  
Fluticasone or  
equivalent for 12  
wks prior to visit 1  
FEV1 50-90% with  
≥ 12% reversibility  
h/o of 1 or >  
asthma  
exacerbations in  
12 mos. prior to  
screening